Research Progress of Omics Technology in the Field of Tumor Resistance: From Singleomics to Multiomics Combination Application

Overview

Journal Zhong Nan Da Xue Xue Bao Yi Xue Ban

Specialty General Medicine

Date 2021 Jul 19

PMID 34275931

Authors

Zeen Sun

Yujie Liu

Qianying Ouyang

Zhaoqian Liu

Yingzi Liu

Affiliations

Soon will be listed here.

Abstract

Drug resistance is the main obstacle in the treatment of many cancers. It is of great clinical significance to study the mechanism of drug resistance and find new targets. Multi-omics mainly includes genomics, epigenomics, transcriptomics, proteomics, metabolomics, and radiomics. In recent years, the research of tumor resistance has made rapid development, which has significantly accelerated the discovery of new targets.

Citing Articles

Full-length transcriptome sequencing of seven tissues of GuShi chickens.

Tian K, Zhang C, Gao C, Shi J, Xu C, Xie W Poult Sci. 2024; 104(2):104697.

PMID: 39721272 PMC: 11732535. DOI: 10.1016/j.psj.2024.104697.

References

Hasin Y, Seldin M, Lusis A . Multi-omics approaches to disease. Genome Biol. 2017; 18(1):83. PMC: 5418815. DOI: 10.1186/s13059-017-1215-1. View

Deyati A, Younesi E, Hofmann-Apitius M, Novac N . Challenges and opportunities for oncology biomarker discovery. Drug Discov Today. 2013; 18(13-14):614-24. DOI: 10.1016/j.drudis.2012.12.011. View

Chong C, Bahcall M, Capelletti M, Kosaka T, Ercan D, Sim T . Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Clin Cancer Res. 2016; 23(1):204-213. PMC: 5203969. DOI: 10.1158/1078-0432.CCR-15-1601. View

Yimit A, Adebali O, Sancar A, Jiang Y . Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs. Nat Commun. 2019; 10(1):309. PMC: 6338751. DOI: 10.1038/s41467-019-08290-2. View

Das D, Ray A, Das A, Song Y, Tian Z, Oronsky B . A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia. 2016; 30(11):2187-2197. PMC: 5093055. DOI: 10.1038/leu.2016.96. View

Beltran H, Wyatt A, Chedgy E, Donoghue A, Annala M, Warner E . Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clin Cancer Res. 2017; 23(22):6802-6811. PMC: 5690882. DOI: 10.1158/1078-0432.CCR-17-1034. View

Fang F, Cardenas H, Huang H, Jiang G, Perkins S, Zhang C . Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs. Cancer Res. 2017; 78(3):631-644. PMC: 5811373. DOI: 10.1158/0008-5472.CAN-17-1492. View

Siret C, Dobric A, Martirosyan A, Terciolo C, Germain S, Bonier R . Cadherin-1 and cadherin-3 cooperation determines the aggressiveness of pancreatic ductal adenocarcinoma. Br J Cancer. 2017; 118(4):546-557. PMC: 5830586. DOI: 10.1038/bjc.2017.411. View

Li Z, Gao X, Peng X, Chen M, Li Z, Wei B . Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy. Sci Adv. 2020; 6(9):eaay4211. PMC: 7043923. DOI: 10.1126/sciadv.aay4211. View

10.

Briffa R, Um I, Faratian D, Zhou Y, Turnbull A, Langdon S . Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers. PLoS One. 2015; 10(12):e0144708. PMC: 4692059. DOI: 10.1371/journal.pone.0144708. View

11.

Hong S, Chan T, Lombardo Y, Corleone G, Rotmensz N, Bravaccini S . Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy. Nat Commun. 2019; 10(1):3840. PMC: 6718416. DOI: 10.1038/s41467-019-11721-9. View

12.

Gil J, Betancourt L, Pla I, Sanchez A, Appelqvist R, Miliotis T . Clinical protein science in translational medicine targeting malignant melanoma. Cell Biol Toxicol. 2019; 35(4):293-332. PMC: 6757020. DOI: 10.1007/s10565-019-09468-6. View

13.

Al Emran A, Marzese D, Menon D, Hammerlindl H, Ahmed F, Richtig E . Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer. Epigenomics. 2019; 11(7):732-737. PMC: 6595545. DOI: 10.2217/epi-2018-0173. View

14.

Zhang X, Chen Y, Hao L, Hou A, Chen X, Li Y . Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine. Cancer Lett. 2016; 381(2):305-13. DOI: 10.1016/j.canlet.2016.08.004. View

15.

Olivier M, Asmis R, Hawkins G, Howard T, Cox L . The Need for Multi-Omics Biomarker Signatures in Precision Medicine. Int J Mol Sci. 2019; 20(19). PMC: 6801754. DOI: 10.3390/ijms20194781. View

16.

Zaborsky N, Gassner F, Hopner J, Schubert M, Hebenstreit D, Stark R . Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development. Leukemia. 2018; 33(4):957-968. PMC: 6477797. DOI: 10.1038/s41375-018-0260-4. View

17.

Kuo M, Gollub J, Sirlin C, Ooi C, Chen X . Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol. 2007; 18(7):821-31. DOI: 10.1016/j.jvir.2007.04.031. View

18.

Teruel J, Heldahl M, Goa P, Pickles M, Lundgren S, Bathen T . Dynamic contrast-enhanced MRI texture analysis for pretreatment prediction of clinical and pathological response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. NMR Biomed. 2014; 27(8):887-96. DOI: 10.1002/nbm.3132. View

19.

Ivanova T, Zouridis H, Wu Y, Cheng L, Tan I, Gopalakrishnan V . Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut. 2012; 62(1):22-33. DOI: 10.1136/gutjnl-2011-301113. View

20.

Obrist F, Michels J, Durand S, Chery A, Pol J, Levesque S . Metabolic vulnerability of cisplatin-resistant cancers. EMBO J. 2018; 37(14). PMC: 6043854. DOI: 10.15252/embj.201798597. View